PBAC Public Summary Documents – September 2022 meeting
Page last updated: 11 November 2022
The Public Summary Document for tixagevimab and cilgavimab (Evusheld®) from the September 2022 Pharmaceutical Benefits Advisory Committee (PBAC) Intracycle meeting is now available.
